ClinicalTrials.gg

Cataplexy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 31 studies for Cataplexy across more than 10 countries. 5 are recruiting or about to start. 19 of them are mainly about Cataplexy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Completed
25
Recruiting
4
Not yet recruiting
1
Status unknown
1

Phase

Phase 3
19
Phase 2
5
Phase 1
1

Where

United States
16
Canada
11
France
10
Switzerland
5
Belgium
5
Spain
5

Who develops what

Add Cataplexy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 2 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Alkermes, Eli Lilly and Harmony Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • May 2027 est.alixorexton · Alkermes, Inc. · Phase 3 registry mapping onlyNCT07455383 A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — primary endpoint: Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level · 150 enrolled
  • 30 Sept 2027 est.cleminorexton · Eli Lilly and Company · Phase 3 registry mapping onlyNCT07598708 A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence — primary endpoint: Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT) · 222 enrolled
  • Oct 2027 est.HBS-301 · Harmony Biosciences Holdings, Inc. · Phase 3 main aimNCT07675135 A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy — primary endpoint: Change in severity of EDS as measured by the Epworth Sleepiness Scale (ESS) · 258 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cataplexy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Stimulants 1 open

Coming up

4studies finish main data collection within a yearall phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Who these studies take

Of the 4 Cataplexy studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 4
AgeWomenMen
100 (0%)0 (0%)
184 (100%)4 (100%)
304 (100%)4 (100%)
404 (100%)4 (100%)
504 (100%)4 (100%)
654 (100%)4 (100%)
752 (50%)2 (50%)
852 (50%)2 (50%)

Across all 31 studies, recruiting or not: 35% stop at 75 or younger and 16% at 65; 35% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 31 of 31. search them.